| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
One type of sulfonamide antibiotic is sulfadimethoxine. Numerous infections, including those of the intestine, bladder, respiratory system, and soft tissues, can be treated with sulfadimethoxine.
|
|---|---|
| References |
[1]. AGUIRRE M, [Sulfadimethoxine in various infections. Results]. Rev Clin Esp. 1961 Sep 30;82:394-9.
[2]. Guerard JJ, et al. Photochemical fate of sulfadimethoxine in aquaculture waters. Environ Sci Technol. 2009 Nov 15;43(22):8587-92. |
| Additional Infomation |
Sulfadimethoxine is a sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. It has a role as an antiinfective agent, an antimicrobial agent, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of pyrimidines, a sulfonamide, a substituted aniline, an aromatic ether and a sulfonamide antibiotic. It is functionally related to a sulfanilamide.
Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies. In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective. Sulfadimethoxine has been reported in Brassica napus with data available. Sulfadimethoxine is a long-acting sulfonamide antibiotic used in veterinary medicine. Sulfadimethoxine inhibits bacterial synthesis of folic acid by competing with para-aminobenzoic acid (PABA) for the binding site on dihydropteroate synthase. A sulfanilamide that is used as an anti-infective agent. See also: Sulfadimethoxine Sodium (has salt form); Ormetoprim; Sulfadimethoxine (component of). Drug Indication For use in the treatment of infections. Pharmacodynamics Sulfadimethoxine has been shown to be effective against streptococci, klebsiella, proteus, shigella, staphylococci, escherichia, and salmonella. |
| Molecular Formula |
C12H14N4O4S
|
|---|---|
| Molecular Weight |
310.328
|
| Exact Mass |
310.073
|
| CAS # |
122-11-2
|
| Related CAS # |
Sulfadimethoxine sodium;1037-50-9;Sulfadimethoxine-d4;1020719-80-5;Sulfadimethoxine-d6;73068-02-7;Sulfadimethoxine-13C6;1334378-48-1
|
| PubChem CID |
5323
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
548.5±60.0 °C at 760 mmHg
|
| Melting Point |
200 °C
|
| Flash Point |
285.5±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.623
|
| LogP |
1.48
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
21
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])(N([H])C1=C([H])C(=NC(=N1)OC([H])([H])[H])OC([H])([H])[H])(=O)=O
|
| InChi Key |
ZZORFUFYDOWNEF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H14N4O4S/c1-19-11-7-10(14-12(15-11)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)
|
| Chemical Name |
4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
|
| Synonyms |
NSC 683544; NSC 683544; NSC 683544
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~322.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2224 mL | 16.1119 mL | 32.2238 mL | |
| 5 mM | 0.6445 mL | 3.2224 mL | 6.4448 mL | |
| 10 mM | 0.3222 mL | 1.6112 mL | 3.2224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
